Janus Henderson Group PLC Aligos Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.04 - $2.14 $1.79 Million - $3.68 Million	-1,720,436 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.08 - $12.2 $1.45 Million - $8.53 Million	-699,177 Reduced 28.9%	1,720,436 $3.7 Million
Q4 2021 Feb 14, 2022	SELL	$11.48 - $17.69 $239,507 - $369,066	-20,863 Reduced 0.85%	2,419,613 $28.7 Million
Q3 2021 Nov 16, 2021	BUY	$14.57 - $17.72 $2.63 Million - $3.2 Million	180,709 Added 8.0%	2,440,476 $37.7 Million
Q2 2021 Aug 16, 2021	BUY	$20.3 - $33.6 $603,234 - $998,457	29,716 Added 1.33%	2,259,767 $45.8 Million
Q1 2021 May 17, 2021	BUY	$19.1 - $34.94 $6.42 Million - $11.7 Million	336,083 Added 17.74%	2,230,051 $48.7 Million
Q4 2020 Feb 16, 2021	BUY	$13.2 - $32.74 $25 Million - $62 Million	1,893,968 New	1,893,968 $50 Million

253K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $751M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.